培美曲塞联合奈达铂一线治疗晚期肺腺癌的临床观察

目的:评价培美曲塞（pemetrexed,PEM）联合奈达铂(nedaplatin,NDP)方案一线治疗晚期肺腺癌的疗效及安全性。方法:采用培美曲塞联合奈达铂治疗93例Ⅲb、Ⅳ期肺腺癌患者，所有患者化疗至少2周期后评价客观有效率（RR）、疾病控制率（DCR）、无疾病进展时间（PFS）、1年及2年生存率，并观察患者的不良反应。结果:93例患者中，完全缓解0例（0.0%），部分缓解48例（51.6%），稳定26例（28.0%），进展19例（20.4%）,客观有效率（RR）为51.6%，疾病控制率(DCR)为79.6%，中位无进展时间（mPFS）为6.3个月，中位总生存时间（mOS）为18个月,1年、2年生存率分别为62%、27%，主要毒副反应为骨髓抑制及胃肠道反应。不良反应可耐受。结论:培美曲塞联合奈达铂方案一线治疗晚期肺腺癌有效、耐受性良好。

Clinical efficacy and safety of pemetrexed plus nedaplatin as the first-line chemotherapy for advanced lung adenocarcinoma

Objective:To evaluate the efficacy and safety of pemetrexed(PEM) and nedaplatin(NDP) as first-line chemotherapy for advanced lung adenocarcinoma.Methods:All 93 patients with advanced lung adenocarcinoma with stage Ⅲb or Ⅳ were treated with pemetrexed and nedaplatin as the first-line chemotherapy.The response rate (RR),disease control rate(DCR),progression-free survival(PFS),1-year survival rate,2-year survival rate were evaluated after at least 2 cycles treatment,Adverse reactions were observed.Results:Among 93 cases,there were 0 CR,48 PR （51.6%）,26 SD （28.0%）,19 PD (20.4%).The overall response rate was 51.6%,the disease control rate was 79.6%,median PFS was 6.3 months and median overall survivals (mOS) was 18 months,the overall survivals at 1 year,2 year were 62%,27%,The main toxicities were marrow depression and gastrointestinal reaction.The adverse reactions were tolerable.Conclusion:Pemetrexed plus nedaplatin as the first-line treatment was well tolerated and resulted in a clinically meaningful treatment benefit for advanced lung adenocarcinoma.